Date
15 November 2022
Pricing & Market Access: What to Expect in 2023
Patrick Burton, for Pharma Boardroom, reports on a panel discussion at the recent FT Global Pharma and Biotech Summit, including the Foundation's CEO, Jayasree K.Iyer.
Direct links
As part of the panel, Jay discussed global inequity of access, noting that post-COVID, more pharma companies are focusing strategically on expanding access in emerging markets.
The fundamental problems around improved access are still to be addressed, however. Pharmaceutical companies need to integrate access planning early on into their development cycles and more can done to engage generic manufacturers sooner on licensing.
The article mentions the release of the 2022 Access to Medicine Index.
Read the article on the Pharma Boardroom website.